IL10 and neoplasm: The results indicated a decrease in the baseline levels of interleukins (IL) IL-6 and IL-10 and an increase in pro-inflammatory cytokines (IL-5, IL-10, IFN-γ, TNF-α) in ARSI-responsive patients when compared to ARSI-resistant patients (32). IL-8 (CXCL‐8), another pro-inflammatory cytokine released by tumor cells (and macrophages), is significantly higher in cell lines with invasive behavior and metastatic potential such as PC-3 and DU-145 compared to the less invasive LnCAP cells.